Is AOD-9604 FDA approved?

AOD-9604 is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

Is CJC-1295 DAC FDA approved?

CJC-1295 DAC is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

How is AOD-9604 administered in research settings?

In research settings, AOD-9604 is typically administered via the subcutaneous or oral routes. PeptideBase does not provide dosing or administration instructions.

How is CJC-1295 DAC administered in research settings?

In research settings, CJC-1295 DAC is typically administered via the subcutaneous route. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›AOD-9604 vs CJC-1295 DAC

Peptide Comparison

AOD-9604 vs CJC-1295 DAC

Name: AOD-9604 vs CJC-1295 DAC — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

Both are GH / IGF Axis peptides.

AOD-9604

Advanced Obesity Drug 9604

Fat LossNot EvaluatedResearch Only

Half-life: 30–60 minutes

192 providers listed

Full AOD-9604 profile →

CJC-1295 DAC

CJC-1295 with DAC

Fat LossNot EvaluatedResearch Only

Half-life: 6–8 days

No providers listed yet

Full CJC-1295 DAC profile →

Bottom line

AOD-9604 has published research citations on file; CJC-1295 DAC does not yet — the main evidence gap between them.

Quick Verdict

AOD-9604

Evidence

Emerging Evidence

Half-life

30–60 minutes

CJC-1295 DAC

Evidence

Emerging Evidence

Half-life

6–8 days

Which One Should You Choose?

Your goal	Better option
Has published research citations	AOD-9604
Less frequent dosing (longer half-life)	CJC-1295 DAC
Oral administration option	AOD-9604
Lower typical price per mg	AOD-9604
More provider options (192 vs 0)	AOD-9604

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

AOD-9604

CJC-1295 DAC

Mechanism Family

GH / IGF Axis

Half-life

30–60 minutes

6–8 days

FDA Status

not evaluated

Admin Routes

subcutaneous, oral

subcutaneous

Availability

Research Only

Providers

192 listed

None listed

Avail. Notes

HGH fragment 176-191. Drug development terminated 2007 (Phase 3 failure). FDA GRAS notice GRN 000792 for food ingredient use only — not a drug approval. No active NDA. Research chemical.

Long-acting GHRH analog with a Drug Affinity Complex (DAC) modification. No FDA approval. Not on the FDA 503A bulks list. WADA-prohibited as a growth hormone releasing factor. Sold as a research chemical only.

Research Evidence

AOD-9604

PreclinicalAnimal · 1 key study · through 2001

CJC-1295 DAC

No citations on file

Research Citations

AOD-9604

Animal2001 · Endocrinology

The effect of the growth hormone fragment AOD9604 on adipose tissue

CJC-1295 DAC

No citations on file.

About AOD-9604

AOD-9604 stimulates lipolysis and inhibits lipogenesis through mechanisms believed to be independent of the insulin-like growth factor pathway. It appears to mimic the fat-metabolising action of growth hormone without triggering the proliferative effects associated with full GH or GH-releasing peptides. Oral bioavailability has been observed in some formulations, making it of interest for non-injectable protocols.

Research Areas

selective fat tissue lipolysis via GH C-terminal fragment mechanismadipose metabolism stimulation without IGF-1 elevationoriginally developed to isolate GH lipolytic effect from growth effectssubcutaneous injection — reconstitution with bacteriostatic water required

About CJC-1295 DAC

CJC-1295 DAC is a GHRH analog carrying a Drug Affinity Complex (DAC) modification that binds covalently to circulating albumin, greatly extending its plasma half-life relative to unmodified or short-acting GHRH analogs. Through this albumin binding it acts as a long-lasting agonist at pituitary GHRH receptors, associated in research with sustained growth hormone and downstream IGF-1 elevation. This contrasts with the non-DAC form (Mod GRF 1-29), whose action is measured in minutes rather than days.

Research Areas

GH and IGF-1 elevation studied in a single-dose human PK trialsustained GHRH-receptor agonism via albumin bindingextended plasma half-life relative to short-acting GHRH analogsbody-composition and GH-axis research contextssubcutaneous administration in published research

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

AOD-9604

Contraindications

Pregnant Or Nursing

CJC-1295 DAC

Contraindications

Cardiovascular Condition

Suggested Monitoring

IGF-1Fasting glucoseHbA1cInsulin

Research protocols routinely measure IGF-1 to track GH axis activity before and during use. Fasting glucose and insulin are monitored because GH elevation can reduce insulin sensitivity over time.

Price (per mg)

AOD-9604

$8.90/mg

$6.85 – $13.47 range

45 vendors

View price index →Find providers →

CJC-1295 DAC

$11.99/mg

$8.40 – $15.80 range

25 vendors

View price index →Find providers →

Find Providers

Where to source these peptides

Providers offering

AOD-9604

192 listed

Browse directory →

Providers offering

CJC-1295 DAC

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More GH / IGF Axis Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated July 3, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). AOD-9604 vs CJC-1295 DAC — Per-mg Price Comparison. Retrieved July 5, 2026, from https://peptidebase.io/peptides/compare/aod-9604/cjc-1295-dac

https://peptidebase.io/peptides/compare/aod-9604/cjc-1295-dac Methodology License Download JSON Download CSV